Advances in therapeutics for chronic hepatitis B

被引：0
作者：
Ninghan Yang
Antonio Bertoletti
机构：
[1] Agency for Science,Viral Hepatitis Laboratory, Singapore Institute of Clinical Sciences (SICS)
[2] Technology and Research (A*STAR),Emerging Infectious Disease (EID) Program
[3] Duke-NUS Graduate Medical School,undefined
来源：
Hepatology International | 2016年 / 10卷
关键词：
Chronic hepatitis B; Hepatitis B virus; Viral replication; Antiviral drugs; Immunity; Immunotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Chronic hepatitis B infection remains a major disease burden globally, and leads to high risk of hepatocellular carcinoma development. Current therapies of nucleot(s)ide analogues and interferon alpha treatment remain limited in their efficacy. Several key findings in the hepatitis B virus (HBV) life cycle have led to the development of novel antiviral drugs to inhibit viral replication and persistence. In addition, recent studies on HBV-specific innate and adaptive immune responses have advanced development of immunotherapy to restore immune mediated virus control in chronic hepatitis B patients. In this review, we discuss potential new therapeutic strategies targeting HBV or the host immune system that might lead to a sustained cure for chronic hepatitis B.
引用
收藏
页码：277 / 285
页数：8
相关论文
共 466 条
[1]  
El-Serag HB(2012)Epidemiology of viral hepatitis and hepatocellular carcinoma Gastroenterology 142 1264-1273.e1
[2]  
Ott JJ(2012)Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity Vaccine 30 2212-2219
[3]  
Stevens GA(2012)Management of HCC J Hepatol 56 75-87
[4]  
Groeger J(1975)Purified and inactivated human hepatitis B vaccine: progress report Am J Med Sci 270 401-404
[5]  
Wiersma ST(2004)Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 97-107
[6]  
De Lope CR(2002)Global control of hepatitis B virus infection Lancet Infect Dis 2 395-403
[7]  
Tremosini S(2001)Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience Vaccine 19 2055-2060
[8]  
Forner A(2008)Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors J Hepatol 48 335-352
[9]  
Reig M(2007)Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans Hepatology 46 1759-1768
[10]  
Bruix J(2012)Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus Elife 2012 1-28
12345678910